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Until the late 1990s, aerosol therapy consisted of beta2-adrenergic agonists, anti-cholinergics, steroidal and
non-steroidal agents, mucolytics and antibiotics that were used to treat patients with asthma, COPD and cystic
fibrosis. Since then, inhalation therapy has matured to include drugs that: (1) are designed to treat diseases outside
the lung and whose target is the systemic circulation (systemic drug delivery); (2) deliver nucleic acids that lead to
permanent expression of a gene construct, or protein coding sequence, in a population of cells (gene therapy); and
(3) provide needle-free immunization against disease (aerosolized vaccination). During the evolution of these
advanced applications, it was also necessary to develop new devices that provided increased dosing efficiency and
less loss during delivery. This review will present an update on the success of each of these new applications and
their devices. The early promise of aerosolized systemic drug delivery and its outlook for future success will be
highlighted. In addition, the challenges to aerosolized gene therapy and the need for appropriate gene vectors will
be discussed. Finally, progress in the development of aerosolized vaccination will be presented. The continued
expansion of the role of aerosol therapy in the future will depend on: (1) improving the bioavailability of
systemically delivered drugs; (2) developing gene therapy vectors that can efficiently penetrate the mucus barrier
and cell membrane, navigate the cell cytoplasm and efficiently transfer DNA material to the cell nucleus;
(3) improving delivery of gene vectors and vaccines to infants; and (4) developing formulations that are safe for
acute and chronic administrations.
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There are many advantages to administering medications
to the lung as an aerosol. These include: a more rapid
onset of action for short-acting bronchodilators, compared
to oral therapy; high local concentration by delivery dir-
ectly to the airways; needle-free systemic delivery of drugs
with poor oral bioavailability; and pain- and needle-free
delivery for drugs that require subcutaneous or intraven-
ous injection. Traditional aerosol therapies with the lung
as the target consist of short-acting β2-adrenergic agonists
and long-acting β2−adrenergic agonists (LABA), anticho-
linergics, inhaled corticosteroids (ICSs), nonsteroidal anti-
inflammatories, antibiotics and mucolytics. Devices that
are available to deliver these drugs include pressurizedCorrespondence: blaube@jhmi.edu
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in any medium, provided the original work is pmetered-dose inhalers (pMDIs), used either alone, or
attached to spacers, or valved holding chambers (VHCs),
breathactuated (BA)-pMDIs, dry powder inhalers (DPIs),
jet nebulizers, vibrating mesh nebulizers and soft mist
inhalers. Well-established treatment guidelines for the
management of asthma [1] and chronic obstructive pul-
monary disease (COPD) [2] each recommend inhaled
therapy as the primary route to administer these medica-
tions. Treatment guidelines for cystic fibrosis (CF) also
include recommendations for inhalation of aerosolized
medications [3,4]. Guidelines for inhalation therapy to
treat these diseases will not be covered in this review. A
comprehensive presentation of old and newly-approved
devices and their correct use in treating these diseases has
also been published [5] and will not be included in this
review. This review will focus on the newest applications
for aerosol therapy by oral inhalation. When possible,n Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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ies, will be highlighted and delivery devices will be
included if they are a new design and critical to the suc-
cess of the application. Updates on new applications for
intranasal therapy are beyond the scope of this review and
can be found in several referenced articles [6-14].
New applications for oral inhalation now include drugs
that: (1) target the systemic circulation as a means to treat
disorders unrelated to the lung (systemic drug delivery by
inhalation); (2) deliver nucleic acids that lead to perman-
ent expression of a gene construct, or protein coding
sequence, in a population of cells within the lung, thereby
reversing or preventing a disease process (aerosolized gene
therapy); and (3) provide needle-free immunization and
prevention against infectious diseases (vaccination by in-
halation). Since first reviewing this subject in 2005 [15],
each of these new applications has met with varying
degrees of success in terms of achieving clinical efficacy
and commercialization. This brief review provides an up-
date on the status and challenges facing each of these new
applications and focuses on an example that is furthest
along in development and/or affects the most people.
Within each example are success stories, failures and les-
sons to be learned. Addressing those lessons will enhance
these applications in the future.
Review
Systemic drug delivery by inhalation
Because of the many advantages to aerosol therapy men-
tioned above, a number of systemically active drugs have
been developed as possible candidates for aerosol deliv-
ery through the lung into the systemic circulation. For
these drugs, it is important that delivery lead to adequate
systemic absorption with no irritability, or damage, to
the airways or alveoli. Drugs that have been tested
include opioids for pre- and post-operative analgesia,
dihydroergotamine (DHE) for acute treatment of migraine,
interferon β to treat multiple sclerosis, leuprolide acetate
to treat prostatic cancer, infertility and post-menopausal
breast cancer, calcitonin to treat postmenopausal osteopor-
osis, growth hormone releasing factor to treat pituitary
dwarfism and insulin to treat diabetes.
A few of these drugs have shown promise in human
trials and some have been commercialized. Opioids such
as morphine and fentanyl have been tested as a liquid
aerosol generated by traditional jet nebulizers [16] and by
the AERx® vibrating mesh prototype nebulizer [17]. The
usefulness of inhaled opioids lies in the elimination of an
intravenous catheter with the potential of providing
rapid-onset, patient-controlled analgesia. A large variabil-
ity in absorption was reported with jet nebulizer adminis-
tration [16], which likely will limit acceptance as a
method for pre- or post-operative pain control with these
devices. Pain management was more predictable with theAERx® device (Aradigm Corp., Hayward, CA, USA) [17].
Another pain management drug, DHE, has proven super-
ior to placebo for the acute treatment of migraine in a
phase 3, double-blinded, multicenter study [18]. In that
study, a novel formulation of DHE (LEVADEX™, MAP
Pharmaceuticals, Mountain View, CA, USA) was delivered
to the systemic circulation using the TEMPO® pMDI
(MAP Pharmaceuticals). Calcitonin has been successfully
delivered to the systemic circulation intranasally [7,8] and
is now available as Miacalcin® (Novartis Pharmaceuticals
Corp, East Hanover, NJ, USA) nasal spray to treat post-
menopausal osteoporosis in females greater than 5 years
post menopause.
Best example of systemic drug delivery by aerosolization:
treating diabetes with oral inhalation of insulin
Although there are several other successful drugs that
have been administered to the systemic circulation by
inhalation, the best example of the expanding role of
aerosol therapy into systemic drug delivery is treating
diabetes with oral inhalation of insulin. This is because
this route of administration has the potential to eliminate
subcutaneous (SC) injection of insulin for a significantly
large patient population. An estimated 370 million people
worldwide have diabetes [19] and the majority of these
have non-insulin dependent diabetes mellitus (NIDDM),
or type-2 diabetes. The goal for the treatment of type-2
diabetes is to maintain glucose control in the normal
range to prevent long-term complications. Typically, the
first line of treatment is oral anti-diabetic medications.
Eventually, anti-diabetic medications fail and type-2
patients need to administer insulin SC four times/day
(i.e. before meals and at bedtime) to achieve good con-
trol. Because injection hurts, compliance with treatment
is often reduced. More importantly, patients who would
benefit from early intervention with insulin treatment
decline treatment because of the pain and inconvenience
associated with injection.
A second reason why treating diabetes with oral inhal-
ation of insulin is the best example of the expanding role
of aerosol therapy into systemic drug delivery is because
what we now know about systemic drug delivery of pep-
tides by inhalation was learned during the development
of inhaled insulin and the study of its success and early
failure continues to inform future development of sys-
temic drug delivery by inhalation, as well as other new
applications of aerosol therapy.
The notion that insulin could be administered through
the lung to the systemic circulation by inhalation was
investigated in the 1970s [20,21]. From those early trials,
several challenges were identified that needed to be over-
come. These included: (1) determining the appropriate
lung target; (2) determining the inhaled dose that con-
trols blood glucose levels; and (3) developing new devices
Figure 1 The AFREZZA® (MannKind Corporation, Valencia, CA,
USA): a second generation device for delivering dry powder
insulin. It is a drug-device combination product, consisting of AFREZZA
inhalation powder pre-metered into single use dose cartridges and a
lightweight, AFREZZA inhaler. Insulin is placed into the chamber in an
aspirin-like tablet. Closing the device crushes it into a fine powder which
is then inhaled by the patient (downloaded from MannKind website at
http://www.mannkindcorp.com/product-pipeline-diabetes-afrezza.htm).
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several pharmaceutical companies and device manufac-
turers began to address these challenges. Work in ani-
mals showed that the appropriate target for aerosolized
insulin and other drugs delivered through the lung for
systemic administration is the alveolar region [22]. This
is because the alveolar region comprises a resorptive sur-
face of 50-75 m2, which provides a surface area for drug
absorption that is the size of a tennis court. In addition,
mucociliary clearance is minimal in the alveolar region.
Once drug deposits in the alveolar region, the residence
time is long, enhancing the probability of absorption.
Finally, the cell barrier to absorption is extremely thin
(0.1 mm) in the alveolar region, thereby enhancing the
possibility for absorption from the epithelial layer to the
lung vasculature.
By the late 1990s, results from several studies [23-26]
showed that a dose of 1.0 U/kg body weight human regu-
lar insulin aerosol controlled fasting glucose levels and a
dose of 1.5 U/kg body weight controlled postprandial glu-
cose levels. However, this dose posed an early limitation
to this route of administration, since it was approximately
10 times the dose given subcutaneously (i.e. ~0.1 U/kg
body weight).
Nevertheless, the Exubera® Pulmonary Insulin Delivery
System (Pfizer Pharmaceuticals, New York, NY; and
Nektar Therapeutics, San Carlos, CA), was approved by
the U.S. Food and Drug Administration in 2006 for use
in adults with both type 1 and type 2 diabetes and
became commercially available soon thereafter [27,28].
By early 2007, two additional devices and formulations
were in Phase III testing. These included the AERx®
Insulin Diabetes Management System (Novo-Nordisk
A/S, Bagsverd, Denmark; and Aradigm Corp., Hayward,
CA) and the AIR® Inhaled Insulin System (Eli Lilly and
Co., Indianapolis, IN; and Alkermes Inc., Cambridge,
MA) [29-31]. However, between October, 2007 and
May, 2008, production of all three products had been
discontinued.
What went wrong?
1. The cost of inhaled insulin was higher than
injectable insulin. One analysis demonstrated that
Exubera®’s inhaled insulin cost about $5 per day,
compared to $2-3 per day by injection [32]. The
higher cost was due in part to the lower
bioavailability of Exubera® inhaled insulin compared
to SC. The bioavailability of Exubera was only
10-15% of the SC dose [26].
2. Safety became an issue. Studies with Exubera® that
lasted 6 months, showed increased insulin binding
antibodies, coughing and a reduction in diffusing
capacity, compared to injected insulin [33].However, longer-term studies showed that
reductions in lung function parameters were small,
non-progressive and reversible with discontinuation
of treatment [33].
3. Sales in the U.S. of Exubera® were lower than
expected, perhaps because of the cost, or safety
issues, or because few patients, or care givers,
realized the advantages of this route of
administration compared to injection therapy.
Second generation delivery system for inhaled insulin
AFREZZA® is a pocket-size device developed by MannKind
Corporation (Valencia, CA, USA) (Figure 1) [34]. It is a
second generation delivery system for inhaled insulin with
several advantages over earlier generations. First, it delivers
microparticles (Technospheres™) of insulin. Technosphere™
insulin particles (human regular insulin loaded onto a
fumaryl diketopiperazine molecule) are optimized for
deposition in the alveolar region of the lung. Greater
than 90% of the particles are in the respirable range, with
a mean particle diameter of 2.5 μm [35]. Bioavailability of
this new formulation is also estimated to be 24-28% of SC
[36] which is higher than for human regular insulin
delivered by the Exubera® device. Unlike the Exubera®,
it is small and portable and appears to be easier to use.
In a recent clinical trial, the change in HBA1C for 211
type 2 patients after 52 weeks on prandial inhaled
Technosphere plus bedtime insulin glargine was similar
and non-inferior to that of 237 patients who
were injected twice daily with biaspart insulin (70%
insulin aspart protamine suspension and 30% insulin
aspart) (Figure 2A and 2B) [36]. In addition, weight gain
was lower and hypoglycemic events were fewer on
Figure 2 Results from recent clinical trial with inhaled Technosphere insulin plus insulin glargine. (A) Glycosylated hemoglobin (HbA1c)
values over 52 weeks for patients who were treated with inhaled Technosphere insulin plus insulin glargine versus patients who were treated with
Biaspart insulin by SC; (B) Change in fasting plasma glucose from baseline for two patient groups over 52 weeks (from Reference [36] with Permission).
Laube Translational Respiratory Medicine 2014, 2:3 Page 4 of 12
http://www.transrespmed.com/content/2/1/3Technoshpere compared to patients on injected insulin.
Thirty-two percent of patients treated with Technosphere
reported cough compared to 14% of patients treated with
injected insulin. Most cough events occurred during the
first 10 minutes of inhalation and declined to about 2/week
by week 6. There were no differences between treatment
groups in terms of pulmonary function changes. A recent
review based on a MEDLINE search of studies relevant to
Technosphere insulin concludes that it is has a pharmaco-
kinetic profile suitable to meet prandial insulin needs in
patients with diabetes [37]. The company is awaiting FDA
approval for mealtime glucose control only. If approved, it
could lead to earlier treatment of diabetes with insulin for
patients who have resisted such treatment due to fear of,
or pain associated with, injection therapy.
Future directions
To insure satisfactory outcomes and patient acceptability of
systemic drug delivery by aerosolization in the future, it is
clear that the bioavailability of expensive drugs like insulin
with relatively low bioavailability needs to be improved. Sug-
gestions for improving bioavailability include: better target-
ing of the alveolar region with nanoparticle (<0.1 μm in
diameter) formulations, or formulations containing porous
particles that have aerodynamic characteristics similar to
extrafine particles (~1.0 μm in diameter); and enhancing ab-
sorption by adding absorption enhancers that do not dam-
age lung tissue. Several additives that have been tested in
rats appear to enhance absorption and permeation and may
be appropriate to improve absorption in future pulmonary
protein formulations. These include endogenous surfactants
such as DPPC [38,39], citric acid [40], and hydroxypropyl-
cellulose [41].
It is also clear that: (1) formulations are needed that
do not produce cough, or changes in lung function, andare safe for acute and chronic administrations; (2) the
device should be small, portable and easy to use; (3) the
total cost of the device and formulation should be simi-
lar in cost to the injection product; and (4) patients and
physicians should be well-educated in terms of the
advantages of this route of a dministration compared to
injection therapy to ensure compliance.
Aerosolized gene therapy
The lung is an important target organ for gene therapy.
This is because there are a number of lung diseases that
could benefit from this type of treatment. These include:
lung cancer, asthma, cystic fibrosis and alpha-1-antitrypsin
deficiency. The goal of aerosolized gene therapy is to cor-
rect the lung disorder with delivery of a functional copy of
the aberrant gene to the appropriate target within the
lung.
Viral vectors versus non-viral vectors for gene therapy
As with systemic drug delivery by aerosolization,
aerosolized gene therapy will likely require repeat dos-
ing. In order to avoid lung damage as a result of repeat
therapy, it is important that the vector that is selected
to deliver the functional genetic material does not
cause immune responses from the host, or lead to
mutagenesis over time. Although there are a number of
viral and non-viral vectors that are available for aerosoliza-
tion that can deliver the functional genetic material, the
identification of safe vectors has been one of the major
challenges to the development of aerosolized gene therapy
[42,43]. Viral vectors include retroviruses, lentiviruses,
adenoviruses (Ad) and adeno-associated viruses (AAV).
Retroviruses are capable of long-term gene expression
following genomic integration but only in non-dividing
cells, whereas, lentiviruses are capable of long-term gene
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ever, both types of viruses present a high risk of insertional
mutation leading to oncogenesis. Adenoviruses infect non-
replicating cells, show potential for persistent expression
and present low risk of insertional mutagenesis. However,
they can trigger a strong immune response by the host.
Unlike adenoviruses, AAV do not trigger a strong immune
response by the host, but they have a small packaging
capability (~4.7 kb), so they are limited in the amount of
genetic material they can carry, and they have reduced
efficacy with repeat-administration.
Non-viral vectors are carrier molecules that are either
cationic lipids, or cationic polymers, that bind to nega-
tively charged plasmid DNA and either encapsulate or
condense the DNA to generate lipoplexes and polyplexes.
Non-viral vectors are generally less efficient than viral
vectors because they lack specific components that could
help with endosomal escape, movement through the
cytoplasm and nuclear uptake. The simpler composition
of non-viral vectors, however, may have an advantage
over viral vectors, since they are free of non-human com-
ponents, making re-administration potentially more suc-
cessful [44,45].
Of the vectors available for delivering genetic material
for gene therapy, AAV vectors have been the most uti-
lized in terms of animal experiments and clinical trials.
Currently, the most common carrier is the viral vector
AAV2, but recent studies suggest that AAV2 with capsids
from serotypes 1, 5 and 6 may be more efficient in trans-
ducing airway epithelial cells than AAV2 [46,47]. Some
progress has been made in improving non-viral gene
transfer [48], but more safety data is needed before they
can be safely administered to humans on a chronic basis.
There are currently no dry-powder, or metered-dose
inhaler formulations for any vector-drug combination.
Therefore, the field is further limited by delivery in a
liquid formulation using a nebulizer.
Best example of aerosolized gene therapy: treating cystic
fibrosis (CF)
Development of aerosolized gene therapy for lung cancer
and alpha-1-antitrypsin deficiency has not progressed be-
yond the preclinical stage. Results from clinical trials
with early therapies have not shown efficacy. On the
other hand, aerosolized gene therapy for treating cystic
fibrosis has had some success in clinical trials and details
of those efforts are reported here. Approximately 70,000
people worldwide have cystic fibrosis (CF), an inherited,
autosomal recessive disease. Mutations in the cystic fi-
brosis transmembrane conductance regulator (CFTR)
gene lead to loss of chloride, sodium and water transport,
impaired mucus removal, obstructed airways, chronic
infection and end stage lung disease. The goal of
aerosolized gene therapy in treating cystic fibrosis is torestore CFTR function and normal chloride channel
function in the lungs.
Over the years, there have been a number of challenges
to aerosol delivery of vectors carrying intact CFTR com-
plementary DNA (cDNA). First, there has been the
challenge of delivering an adequate dose to infants, who
are an important target population. This is because identi-
fication of infants who are afflicted with CF is now pos-
sible at birth and early gene therapy holds the promise of
correcting the abnormality before irreversible lung dam-
age can occur. However, due to anatomic, physiologic and
behavioral factors, delivery of aerosols to infants is chal-
lenging and highly variable. Gene transfer therapy is likely
to be extremely expensive, so improving delivery efficiency
and reducing variability of delivery to small children will
result in less waste and help insure the desired effect.
Another challenge has been uniform delivery of the drug
vector to the lungs of adult patients with CF. Disease in
adults with CF is significantly more severe, compared to
children with CF (Figure 3) [49]. Increased disease severity
is shown by a lower percent forced expiratory volume
in one second (FEV1) in adults, compared to children.
Increased severity in disease leads to uneven distribution of
the drug vector, with areas of the lung that are unob-
structed receiving a higher dose of vector than regions that
are partially, or fully obstructed (Figure 4). Such uneven
distribution of the drug vector could make treatment less
efficacious. These same challenges are likely to apply to
treating infants, or adults with obstructed airways, with
aerosolized gene vectors for other lung diseases.
Additional challenges to aerosolized gene therapy for
CF that likely apply to aerosolized gene therapy for other
lung diseases include delivery of DNA through the
mucus barrier. The mucus barrier is thick and viscous in
patients with CF, and in patients with chronic obstructive
lung disease (COPD), there is excess mucus production.
Gene vectors whose target is the airway epithelial cell
must be able to penetrate beyond the mucus barrier to
reach their cell target. Another challenge is the need for
vectors that recognize receptors on the apical surface of
airway epithelial cells. Many vectors only recognize
receptors on the basal-lateral surfaces, which are very
difficult to access. The gene vector must deliver DNA to
the cell nucleus. To do this, the vector must penetrate
the cytoplasmic membrane, overcome cytoplasmic prote-
ases and penetrate the nuclear membrane.
To date, 24 clinical trials with aerosolized gene vectors
have been carried out since the cloning of the CF gene in
1989. Nine Ad CF gene therapy trials were carried out in
the upper and lower airways of CF patients between 1993
and 2001 [50]. These trials showed that low level gene
transfer can be achieved in some patients, but administra-
tion resulted in lung inflammation and induced humoral
and cellular immune responses, affecting the efficacy of
Figure 3 Percent of people with cystic fibrosis by age with normal/mild forced expiratory volume in one second (FEV1), moderate FEV1
and severe FEV1. The majority of children have FEV1 values in the normal to mild range, indicating mild disease and mild airway obstruction.
Adults age 18–29 and 30+ have FEV1 values in the moderate to severe range, indicating severe disease and increased airway obstruction
(downloaded from Cystic Fibrosis Foundation website at http://www.cff.org/UploadedFiles/Research/ClinicalResearch/2011-Patient-Registry.pdf).
Laube Translational Respiratory Medicine 2014, 2:3 Page 6 of 12
http://www.transrespmed.com/content/2/1/3re-administration. These shortcomings have not been
overcome [48].
Between 1999 and 2007, six clinical trials were carried
out with the AAV2 serotype [51]. Acute administration
appeared to be safe, but assessment of the efficiency of
vector-specific expression was lacking and in another
large trial there was no improvement in lung function
[52]. Moreover, repeat dosing with the AAV2 serotype
does not appear to be possible due to the development of
an anti-viral immune response.
Nine clinical trials have evaluated non-viral gene transfer
to the upper and lower airways of CF patients [50]. For the
most part these were proof of principle and Phase I safety
studies. None of the trials were designed to assess clinical
efficacy. A recent review article provides detailed informa-
tion about these clinical trials, what vectors were used and
their drawbacks [45].Figure 4 Gamma camera images of four adult patients with
cystic fibrosis and different FEV1 values showing distribution of
an aerosol containing the radioisotope 99mtechnetium. Uniform
deposition of aerosolized radioisotope is reduced in patients with
low FEV1 and severe obstruction (from Reference [15] with Permission).Recent developments in the UK hold new promise
for improving CF lung disease through gene therapy
[45]. The UK CF Gene Therapy Consortium (http:
www.cfgenetherapy.org.uk) is currently conducting the
only active CF gene therapy clinical trial. This will be a
multi-dose clinical trial using the non-viral cationic
lipid formulation GL67A (Genzyme, Cambridge, MA, USA)
with certain modifications, including CpG-depletion and the
incorporation of an hCEFI promoter called pGM169 [45].
CpG-free plasmids reduce inflammation and lead to long-
acting gene expression when administered to the mouse
lung [45,53]. The hCEFI promoter also prolongs gene
expression in mice [53]. A safe dose for a multi-dose
double-blinded placebo-controlled trial of this new for-
mulation has been determined and trial participants
have been recruited [54]. Participants will be treated
with 12 monthly doses delivered by the AeroEclipseII
Breath-Actuated Nebulizer (Trudell Medical Instruments,
London, Canada) over a year period [55].
Future directions
Successful correction of lung diseases with inhaled gene
therapy remains elusive. A number of challenges must
be overcome before pulmonary gene therapy becomes a
reality. These include: (1) developing gene vectors that
can more efficiently penetrate the mucus barrier and cell
membrane, navigate the cell cytoplasm and transfer
DNA material to the cell nucleus; (2) improving delivery
of gene vectors to infants; and (3) developing formula-
tions that are safe and effective for acute and chronic
administrations.
Vaccination by inhalation
The rationale for aerosolized vaccination is based on the
following advantages over injection therapy, particularly
in developing countries. First, vaccination by inhalation
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ber of needles that are used in mass campaigns in devel-
oping countries. Secondly, it prevents the spread of blood
borne diseases such as hepatitis B and HIV, which can be
transmitted by improper use and handling of used sharps.
Thirdly, administration of a vaccine via the aerosol route
has less need for medical personnel, or a medical setting,
compared to administration by injection, and should
facilitate vaccination implementation in developing
countries. Another rationale for aerosolized vaccin-
ation is that it induces protection by exposure of the
airway mucosa to agents that directly affect the lungs
and cause diseases such as tuberculosis, diphtheria,
pneumococcal pneumonia, measles, mumps and ru-
bella. Airway mucosal vaccination may also represent a
potential approach for immunizing against agents that
do not directly affect the lungs such as human papil-
loma virus, or hepatitis B virus, by inducing relevant
antibodies in the serum.
Because of the advantages to aerosolized immunization,
a number of vaccines are being tested for feasibility and
efficacy via the pulmonary route. Many of these are still in
preclinical stages and have not progressed to clinical trials.
Brief descriptions of results from these early studies are
described here. Hepatitis B virus infection remains an im-
portant global health concern despite effective vaccines
that are available by injection. But, for reasons mentioned
above, injection therapy for hepatitis B is restricted in the
developing world. Although inhalation therapy is of inter-
est, it is unknown if immunization is possible by inhalation
of hepatitis vaccine. A few animal studies have begun to
investigate the effects of particle size and formulation on
this route of administration. A liquid suspension of
hepatitis B vaccine PLGA (poly-D,L-lactide-co-glycolide)
or PLA (poly-lactic acid), nanoparticles of different sizes
administered to rats using a Microsprayer® (Penn-Century,
Inc., Wyndmoor, PA, USA) resulted in humoral and mu-
cosal immune responses that varied with particle size and
hydrophobicity of the polymers used [56]. A dry powder
of hepatitis B vaccine nanoparticles administered by the
Insufflator® (Penn-Century, Inc.) led to lower IgG and
higher IgA in guinea pigs, compared to intramuscular
injection [57]. A liquid suspension of PLGA microspheres
of hepatitis B vaccine, administered by Microsprayer®,
showed that immunogenicity in rats was a function of par-
ticle size [58].
Safety and tolerance of intranasal administration of hepa-
titis B vaccine (NASVAC), comprised of hepatitis B virus
(HBV) surface (HBsAg) and core antigens (HBcAg), with
Accuspray® (Becton Dickinson and Company, Franklin
Lakes NJ, USA) has been demonstrated in a small group of
healthy volunteers [59]. However, large, randomized con-
trolled clinical trials with this inhaled hepatitis B vaccine
are needed to show efficacy.Administration of diphtheria vaccine by inhalation is of
interest because it would avoid the high probability of a
local reaction that occurs at the site of vaccination with
intramuscular injection. It would be a safer route of ad-
ministration in developing countries and might induce
mucosal IgA antibody which could bind to the exotoxin
released by Cornyebacterium diphtheriae, preventing it
from entering and colonizing the airway mucosal mem-
brane [60]. Inhaled diphtheria vaccine is in early stages of
development, but a dry powder formulation of diphtheria
CRM-197 antigen with PLGA as an adjuvant, adminis-
tered using the Insufflator®, resulted in lower IgG in the
sera and higher IgA in the BAL of guinea pigs, compared
to intramuscular injection [60].
The urgency to address drug-resistant TB has led to a
resurgence in interest in inhalation as a route of adminis-
tration for anti-TB drugs to treat TB as well as vaccines
to prevent TB. A recent review of the status of anti-TB
drugs is provided by Hickey et al. [61]. Small clinical
trials suggest that immunotherapy with inhaled interferon-
gamma [62], or inhalation of a dry powder formulation
of the antibiotic capreomycin with a hand-held inhaler
(Cyclohaler®, Plastiape, Italy), might be beneficial to TB pa-
tients [63]. However, large, randomized controlled clinical
trials are needed to further evaluate efficacy and safety.
Mucosal immunity for protection against TB has
been theorized, but is yet unproven in clinical trials.
Nevertheless, a number of novel formulations including
nanoparticles and dry powders of antigen/adjuvant com-
binations are being evaluated in animal models [64]. Two
examples are provided here. A suspension of nanoparti-
cles (i.e. particles <0.1 μm in diameter) conjugated with
Ag85B tuberculosis antigen and delivered through the
nostrils of mice showed better protection against subse-
quent challenge, compared to intradermal delivery [65].
A dry powder of live- attenuated tuberculosis vaccine
bacille Calmette-Guerin (BCG), administered by an
Insufflator®, resulted in a significantly reduced bacterial
burden and lung pathology in guinea pigs subsequently
challenged with virulent Mycobacterium tuberculosis,
compared to untreated animals and control animals im-
munized with the standard parenteral BCG [66]. Further
investigation is needed to bring these products forward.
Immunization against the human papilloma virus by in-
halation has been tested in a small clinical trial by Nardelli-
Haefliger and colleagues [67]. This was a dose escalation
study of intranasal and oral inhalation of a human papil-
loma virus-like particle (HPV16 VLP) vaccine aerosol.
Nasal administration was via a Devilbiss® nebulizer sprayed
into each nostril. Pulmonary administration was achieved
using a sonication-type nebulizer and mouthpiece. Healthy
adult female volunteers inhaled two doses of the vaccine
on day 0 and day 2 by nose, or mouth. Doses escalated
from 2 μg to 50 μg and 250 μg. Volunteers who inhaled
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ation) and the magnitude of their serum IgG and IgA
responses was similar to that seen with an historically-
treated group that was administered 50 μg by intramuscular
injection. Lower doses by oral inhalation were less effective
and intranasal vaccination was poorly immunogenic for
most volunteers. These data raise the possibility that ad-
ministration of the VLP vaccine via oral inhalation may
offer an alternative to systemic immunization. More trials
are needed to confirm that aerosol vaccination is safe, im-
munogenic and protective against genital HPV infection.
Gordon et al. [68] compared the effect of intramuscular
vs. inhaled 23-valent pneumococcal capsular polysaccharide
vaccine (23-PPV) on pulmonary mucosal immunoglobulin
levels. Vaccine was delivered by jet nebulizer (Sidestream®,
Respironics, Murrysville, PA, USA). Bronchoalveolar lavage
(BAL) and serum were collected from 33 adults before and
1 month after injected (n=16) or inhaled (n=17) 23-PPV.
Levels of pneumococcal capsule-specific IgG and IgA to
types 1, 9V and 14 were measured in each sample. Injected
23-PPV produced a significant increase in types 1, 9V and
14 capsule-specific IgG and type 1 IgA in both serum and
BAL. Inhaled vaccine produced no response in either BAL
or serum.
Best example of vaccination by inhalation: preventing
measles with inhaled measles vaccine
Inhaled measles vaccine is furthest along in drug develop-
ment, compared to the other inhaled vaccine candidates
mentioned above and is, therefore, the best example of
vaccination by inhalation. Its development has also been
greatly influenced by lessons learned from the Exubera®
inhaled insulin experience. The worldwide incidence of
measles has been declining for the last ten years. However,
populations in some countries remain unprotected. For
example, an estimated 20 million children worldwide were
under-vaccinated in 2012 [69]. If infants are not ad-
equately immunized against measles, the entire com-
munity will be at risk for measles epidemics.
Over three decades ago, Dr. Albert Sabin and colleagues
proved the feasibility of vaccination by aerosolized measles
vaccine [70,71]. Since then, other trials have demonstrated
that measles vaccine administered by aerosol provides a
superior boosting response compared to vaccination by
injection in school-age children [72,73]. However, studies
performed in infants younger than 10 months of age
showed that seroconversion rates were lower with
aerosolized than subcutaneous vaccine [74]. This may
have been due to an inadequate dose delivered to the
lungs of these infants, since an inefficient nebulizer
and face mask was used in those trials. Thus, a major
challenge to developing an aerosolized vaccine for pre-
venting measles in the developing world is to deliver
an adequate dose to infants.A second challenge to the development of an inhalable
measles vaccine is the need for new delivery devices.
Such delivery devices need to be efficient, portable and
battery operated, since electricity is not readily available
in villages in developing countries. New, efficient, port-
able devices that are battery-operated are now available
for liquid aerosol deliver (i.e. vibrating mesh devices)
and for dry powder delivery. Details about how these
devices operate and their proper use can be found else-
where [5]. However, it is only within the last 4–5 years
that these devices have been incorporated into clinical
trials that are testing the efficacy of inhalable measles
vaccine. Unfortunately, many of these trials have only
recently been completed, or are being completed, and
results are not yet published. An update of the status of
those trials, the formulation of measles vaccine being
tested and the devices that are being used to deliver the
vaccine is provided below.
In the early 2000s, the World Health Organization
(WHO) began work on an aerosolized measles vaccine
that could be used in mass immunization campaigns in
developing countries. The WHO decided to aerosolize
the liquid formulation that was licensed for injection
therapy and had proven effective by inhalation in earlier
studies in Mexico [70,71]. This was the Edmonston-
Zagreb (EZ) live-attenuated measles vaccine. This choice
meant that the WHO did not have to reformulate the
vaccine, which could have resulted in years of additional
testing. After several years of device development in col-
laboration with the U.S. CDC, the Bill and Melinda Gates
Foundation and Aerogen (Galway, Ireland), the WHO
began testing the Aerogen AeronebGo® delivery system
in India. This is a portable, battery-operated vibrating
mesh device with a face mask for infant aerosol delivery
(Figure 5). A Phase III trial in 2,000 children <12 months
old was recently completed. Data are being analyzed and
results will be compared to those obtained with subcuta-
neous (SC) administration of measles vaccine in a similar
age-group.
The possibility of delivering a combination aerosol vac-
cine to protect against measles, mumps and rubella with
the AeronebGo® device has also being conducted [75].
This was an exploratory study to evaluate the safety and
antibody responses to each component of MMR II
(Attenuvax measles live-attenuated vaccine, Jeryl Lynn
mumps live-attenuated vaccine and L-Zagreb mumps live-
attenuated vaccine) in healthy adults 21–38 years of age.
The investigators chose to use the AeronebGo® device be-
cause previous studies with aerosolized Schwarz measles
vaccine (similar to the Attenuvax base sequence) showed
rapid degradation of vaccine potency using a jet nebulizer
and compressed air system. Results from the more recent
study showed that aerosolization of the three components
of MMRII vaccine was safe and produced secondary
Figure 5 The Aerogen Aeroneb Go® delivery system (Aerogen,
Galway Ireland) is being developed to deliver liquid measles
vaccine to children and infants in developing countries. The
device consists of a medication chamber that is located in the
upper part of a plastic holder. The outlet port extends from the
holder and can be fitted with a mouthpiece or facemask. A vibrating
membrane, the generator OnQ®, pumps fluid through small holes
generating aerosol with a median diameter of 3.6 microns. The
control module works with three AA batteries and is connected to
the medication chamber through a removable cord [75].
(Image downloaded from Aerogen website at http:www.aerogen.
com/aeroneb-go.html).
Figure 6 The PuffHaler® (Aktiv-Dry, LLC, Boulder, CO, USA) (A) and th
USA) (B) are two new devices that are being developed to deliver me
developing countries. When the PuffHaler squeeze bulb is compressed, the
through the powder in an aluminum foil blister and the aerosol cloud fills a c
affixed to a facemask from which the subject breathes for 30 s to become va
pressurize the capsule containing the powder vaccine. As the pressure rises, t
captured in the disposable spacer for delivery through a silicone facemask (So
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need to be performed in children.
Within the last 6–8 years, the WHO, the U.S. CDC,
the Bill and Melinda Gates Foundation, the NIH and
Aktiv-Dry, LLC (Boulder, CO, USA) began working on a
powder formulation of the EZ live-attenuated measles
vaccine. The advantage to a powder formulation is that
it does not need refrigeration, which is also often lacking
at sites of mass campaigns in developing countries. The
powder was developed by Aktiv-Dry, LLC. The two de-
vices to deliver the powder are called the PuffHaler® and
the Solovent® and are shown in Figure 6A and 6B. They
were developed by Aktiv-Dry and BD Technologies
(Becton, Dickinson and Company), respectively. Both
devices incorporate a holding chamber that allows the
powder to be actuated and held in place until inhalation
is initiated. Such a holding chamber for a powder aerosol
was first introduced in the Exubera® Pulmonary Insulin
Delivery System that was used to administer insulin aero-
sol. Unlike the Exubera device, these devices are con-
structed of inexpensive materials such that the cost of
delivering dry powder measles vaccine will not cost more
than intramuscular injection administration. Both devices
also include flexible face masks for infant delivery. In a
recent pre-clinical trial, dry powder vaccine delivered by
these two devices provided full protection against mea-
sles infection in Rhesus macaques [76]. A large clinical
trial to test the efficacy of this powder formulation in
humans is currently being planned.
Unlike aerosol applications for systemic drug delivery
and gene therapy, immunization by inhalation does not re-
quire chronic repeat dosing for efficacy. For many vaccines,
immunization may be achieved with 1–2 aerosol treat-
ments followed by a booster treatment. Thus, there is less
concern about the safety of repeated lung dosing withe Solovent® (Becton, Dickinson and Company, Franklin Lakes, NJ,
asles vaccine as a dry powder to children and infants in
silicone rubber burst-valve pops open. The air rushes into the disperser
ollapsed plastic bag reservoir. The aerosol-filled bag is detached and
ccinated (Puff-mask). The syringe of the BD Solovent device is used to
he thin films sealing the capsule rupture, and the powder is expelled and
l-mask) (from Reference [76] with Permission).
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delivery and gene therapy by inhalation. Nevertheless,
safety remains an issue with inhaled vaccines because some
patient populations (e.g. patients with allergic asthma) may
be more sensitive to excipients in the formulations and
care-givers who are immunosuppressed may be more
vulnerable to vaccine exposure than non-immunosuppressed
individuals.
Future directions
Vaccination by inhalation is a promising new method for
immunization. It has already been used in large populations
and appears to be a feasible method for mass vaccinations.
Recent developments in device innovation have made
reliable, portable aerosol dosing in mass campaigns pos-
sible. Improvements in delivery to infants and in the
development of vaccines that do not require refrigeration
(i.e. powders) and are stable at the ambient temperatures
of the tropics could make this the preferred route of
administration for a number of vaccines in the future.
Conclusions
The role of aerosol therapy has changed over the years to
now include systemic drug delivery by inhalation, inhaled
gene therapy and vaccination by inhalation. Each of these
new applications has led to the development of new deliv-
ery devices and achieved varying degrees of success in treat-
ing their disease targets. The continued expansion of the
role of aerosol therapy in the future will depend on: (1)
improving the bioavailability of systemically delivered drugs;
(2) developing gene therapy vectors that can efficiently
penetrate the airway mucus barrier and cell membrane,
navigate the cell cytoplasm and efficiently transfer DNA
material to the cell nucleus; (3) improving delivery of gene
vectors and vaccines to infants; and (4) developing formula-
tions that are safe for acute and chronic administrations.
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